Rawan A Obeidat, Abeer M Rababa'h, Shahd Alguzo, Baraa Sakee, Shereen Hamadneh, Eman Alshdaifat, Ahmed Alhusban
{"title":"胎儿和母体血小板反应蛋白-1 （TSP-1）和血管内皮生长因子（VEGF）血清水平与胎儿和母体选定特征的关系","authors":"Rawan A Obeidat, Abeer M Rababa'h, Shahd Alguzo, Baraa Sakee, Shereen Hamadneh, Eman Alshdaifat, Ahmed Alhusban","doi":"10.2147/RMHP.S528423","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Thrombospondin-1 (TSP-1) and vascular endothelial growth factor (VEGF) are placental glycoproteins involved in angiogenesis and vascular regulation during pregnancy. Dysregulation of these markers has been linked to complications such as preeclampsia and intrauterine growth restriction. In this cross-sectional study, we evaluated maternal and fetal serum levels of TSP-1 and VEGF and their associations with clinical characteristics.</p><p><strong>Methods: </strong>We studied 438 pregnant women with singleton live pregnancies between 28-40 weeks of gestation. Women with fetal anomalies were excluded. Serum levels of TSP-1 and VEGF were measured using enzyme immunoassay. Group comparisons were performed using the Mann-Whitney U and Kruskal-Wallis tests, and correlations were analyzed using Spearman's test.</p><p><strong>Results: </strong>Median maternal and fetal TSP-1 levels were 5.1 [2.6-7.4] ng/mL and 4.7 [2.3-8.9] ng/mL, respectively. Fetal TSP-1 levels positively correlated with maternal TSP-1 (r = 0.27, p < 0.000) and fetal VEGF (r = 0.21, p < 0.000). Lower fetal TSP-1 was observed in women with diabetes mellitus (1.9 vs 4.7 ng/mL, p = 0.042) and higher levels in those with small-for-gestational-age fetuses (8.5 vs 4.7 ng/mL, p = 0.036). Median maternal and fetal VEGF levels were 37.2 [33.3-42.5] pg/mL and 148 [62.9-247.8] pg/mL. A positive correlation was found between maternal and fetal VEGF (r = 0.24, p < 0.000). Lower maternal VEGF was associated with chronic hypertension, gestational diabetes, preterm premature rupture of membranes, and use of methyldopa or metformin. Fetal VEGF was higher in mothers taking thyroxine (220 vs 142.7 pg/mL, p = 0.018) and lower during established labor (114.1 vs 165.5 pg/mL, p = 0.038).</p><p><strong>Conclusion: </strong>Maternal and fetal levels of TSP-1 and VEGF were significantly correlated and influenced by clinical and pharmacologic factors, supporting their potential utility as early biomarkers of pregnancy complications and maternal-fetal health.</p><p><strong>Registration: </strong>Research Registry (UIN: researchregistry6781), April 30, 2021.</p>","PeriodicalId":56009,"journal":{"name":"Risk Management and Healthcare Policy","volume":"18 ","pages":"3235-3248"},"PeriodicalIF":2.0000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12497384/pdf/","citationCount":"0","resultStr":"{\"title\":\"The Association of Fetal and Maternal Thrombospondin-1 (TSP-1) and Vascular Endothelial Growth Factor (VEGF) Serum Levels with Selected Fetal and Maternal Characteristics.\",\"authors\":\"Rawan A Obeidat, Abeer M Rababa'h, Shahd Alguzo, Baraa Sakee, Shereen Hamadneh, Eman Alshdaifat, Ahmed Alhusban\",\"doi\":\"10.2147/RMHP.S528423\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Thrombospondin-1 (TSP-1) and vascular endothelial growth factor (VEGF) are placental glycoproteins involved in angiogenesis and vascular regulation during pregnancy. Dysregulation of these markers has been linked to complications such as preeclampsia and intrauterine growth restriction. In this cross-sectional study, we evaluated maternal and fetal serum levels of TSP-1 and VEGF and their associations with clinical characteristics.</p><p><strong>Methods: </strong>We studied 438 pregnant women with singleton live pregnancies between 28-40 weeks of gestation. Women with fetal anomalies were excluded. Serum levels of TSP-1 and VEGF were measured using enzyme immunoassay. Group comparisons were performed using the Mann-Whitney U and Kruskal-Wallis tests, and correlations were analyzed using Spearman's test.</p><p><strong>Results: </strong>Median maternal and fetal TSP-1 levels were 5.1 [2.6-7.4] ng/mL and 4.7 [2.3-8.9] ng/mL, respectively. Fetal TSP-1 levels positively correlated with maternal TSP-1 (r = 0.27, p < 0.000) and fetal VEGF (r = 0.21, p < 0.000). Lower fetal TSP-1 was observed in women with diabetes mellitus (1.9 vs 4.7 ng/mL, p = 0.042) and higher levels in those with small-for-gestational-age fetuses (8.5 vs 4.7 ng/mL, p = 0.036). Median maternal and fetal VEGF levels were 37.2 [33.3-42.5] pg/mL and 148 [62.9-247.8] pg/mL. A positive correlation was found between maternal and fetal VEGF (r = 0.24, p < 0.000). Lower maternal VEGF was associated with chronic hypertension, gestational diabetes, preterm premature rupture of membranes, and use of methyldopa or metformin. Fetal VEGF was higher in mothers taking thyroxine (220 vs 142.7 pg/mL, p = 0.018) and lower during established labor (114.1 vs 165.5 pg/mL, p = 0.038).</p><p><strong>Conclusion: </strong>Maternal and fetal levels of TSP-1 and VEGF were significantly correlated and influenced by clinical and pharmacologic factors, supporting their potential utility as early biomarkers of pregnancy complications and maternal-fetal health.</p><p><strong>Registration: </strong>Research Registry (UIN: researchregistry6781), April 30, 2021.</p>\",\"PeriodicalId\":56009,\"journal\":{\"name\":\"Risk Management and Healthcare Policy\",\"volume\":\"18 \",\"pages\":\"3235-3248\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2025-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12497384/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Risk Management and Healthcare Policy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2147/RMHP.S528423\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"HEALTH CARE SCIENCES & SERVICES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Risk Management and Healthcare Policy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/RMHP.S528423","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0
摘要
背景：血小板反应蛋白-1 （TSP-1）和血管内皮生长因子（VEGF）是妊娠期参与血管生成和血管调节的胎盘糖蛋白。这些标记物的失调与子痫前期和宫内生长受限等并发症有关。在这项横断面研究中，我们评估了母体和胎儿血清中TSP-1和VEGF的水平及其与临床特征的关系。方法：对438例妊娠28 ~ 40周单胎活产孕妇进行研究。排除有胎儿畸形的妇女。采用酶免疫法检测血清TSP-1和VEGF水平。采用Mann-Whitney U检验和Kruskal-Wallis检验进行组间比较，采用Spearman检验分析相关性。结果：母体和胎儿中位TSP-1水平分别为5.1 [2.6-7.4]ng/mL和4.7 [2.3-8.9]ng/mL。胎儿TSP-1水平与母体TSP-1 （r = 0.27, p < 0.000）、胎儿VEGF水平呈正相关（r = 0.21, p < 0.000）。糖尿病女性胎儿TSP-1水平较低（1.9 vs 4.7 ng/mL, p = 0.042），胎龄小的女性胎儿TSP-1水平较高（8.5 vs 4.7 ng/mL, p = 0.036）。母体和胎儿中位VEGF水平分别为37.2 [33.3-42.5]pg/mL和148 [62.9-247.8]pg/mL。母体与胎儿VEGF呈正相关（r = 0.24, p < 0.000）。母体VEGF降低与慢性高血压、妊娠期糖尿病、胎膜早破和甲多巴或二甲双胍的使用有关。胎儿VEGF在服用甲状腺素的母亲中较高（220 vs 142.7 pg/mL, p = 0.018），而在分娩时较低（114.1 vs 165.5 pg/mL, p = 0.038）。结论：母体和胎儿的TSP-1和VEGF水平受临床和药理学因素的显著相关和影响，支持其作为妊娠并发症和母胎健康的早期生物标志物的潜在用途。注册：Research Registry (UIN: researchregistry6781)， 2021年4月30日。
The Association of Fetal and Maternal Thrombospondin-1 (TSP-1) and Vascular Endothelial Growth Factor (VEGF) Serum Levels with Selected Fetal and Maternal Characteristics.
Background: Thrombospondin-1 (TSP-1) and vascular endothelial growth factor (VEGF) are placental glycoproteins involved in angiogenesis and vascular regulation during pregnancy. Dysregulation of these markers has been linked to complications such as preeclampsia and intrauterine growth restriction. In this cross-sectional study, we evaluated maternal and fetal serum levels of TSP-1 and VEGF and their associations with clinical characteristics.
Methods: We studied 438 pregnant women with singleton live pregnancies between 28-40 weeks of gestation. Women with fetal anomalies were excluded. Serum levels of TSP-1 and VEGF were measured using enzyme immunoassay. Group comparisons were performed using the Mann-Whitney U and Kruskal-Wallis tests, and correlations were analyzed using Spearman's test.
Results: Median maternal and fetal TSP-1 levels were 5.1 [2.6-7.4] ng/mL and 4.7 [2.3-8.9] ng/mL, respectively. Fetal TSP-1 levels positively correlated with maternal TSP-1 (r = 0.27, p < 0.000) and fetal VEGF (r = 0.21, p < 0.000). Lower fetal TSP-1 was observed in women with diabetes mellitus (1.9 vs 4.7 ng/mL, p = 0.042) and higher levels in those with small-for-gestational-age fetuses (8.5 vs 4.7 ng/mL, p = 0.036). Median maternal and fetal VEGF levels were 37.2 [33.3-42.5] pg/mL and 148 [62.9-247.8] pg/mL. A positive correlation was found between maternal and fetal VEGF (r = 0.24, p < 0.000). Lower maternal VEGF was associated with chronic hypertension, gestational diabetes, preterm premature rupture of membranes, and use of methyldopa or metformin. Fetal VEGF was higher in mothers taking thyroxine (220 vs 142.7 pg/mL, p = 0.018) and lower during established labor (114.1 vs 165.5 pg/mL, p = 0.038).
Conclusion: Maternal and fetal levels of TSP-1 and VEGF were significantly correlated and influenced by clinical and pharmacologic factors, supporting their potential utility as early biomarkers of pregnancy complications and maternal-fetal health.
Registration: Research Registry (UIN: researchregistry6781), April 30, 2021.
期刊介绍：
Risk Management and Healthcare Policy is an international, peer-reviewed, open access journal focusing on all aspects of public health, policy and preventative measures to promote good health and improve morbidity and mortality in the population. Specific topics covered in the journal include:
Public and community health
Policy and law
Preventative and predictive healthcare
Risk and hazard management
Epidemiology, detection and screening
Lifestyle and diet modification
Vaccination and disease transmission/modification programs
Health and safety and occupational health
Healthcare services provision
Health literacy and education
Advertising and promotion of health issues
Health economic evaluations and resource management
Risk Management and Healthcare Policy focuses on human interventional and observational research. The journal welcomes submitted papers covering original research, clinical and epidemiological studies, reviews and evaluations, guidelines, expert opinion and commentary, and extended reports. Case reports will only be considered if they make a valuable and original contribution to the literature. The journal does not accept study protocols, animal-based or cell line-based studies.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
